

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

5 - 11 October 2026



India Targets Chinese Chemical Imports with Anti-Dumping Duties

India's Ministry of Commerce launched anti-dumping investigations and rulings against seven categories of Chinese chemical and pharmaceutical products. Covering key raw materials such as refrigerants and active pharmaceutical ingredients, the measures impose provisional duties up to €3,550 (\$3,967) per ton on synthetic fragrances to safeguard domestic supply chains. **(ChemNet Chemical Headlines)**

EU Launches Anti-Dumping Probe into Chinese PVC Imports

The European Commission formally initiated an anti-dumping investigation into polyvinyl chloride (PVC) resin imported from mainland China, South Korea, Mexico, and Taiwan. Following local industry complaints, preliminary rulings expected within eight months could impose provisional tariffs, escalating trade barriers and risking European market share for Chinese exporters. **(ChemNet Chemical Headlines)**

EU Initiates Anti-Dumping Probe into Chinese Cellulose Ether

Following complaints from European producers, the European Commission launched an anti-dumping investigation into cellulose ether imported from China and South Korea. Essential for construction materials, coatings, and pharmaceuticals, China exported 211,600 tons of the chemical in 2025. The ongoing probe poses significant risks to Chinese manufacturers' European export orders and market share. **(ChemNet Chemical Headlines)**

Jiangsu Hengrui Licenses Weight-Loss Candidate to Novo Nordisk

Jiangsu Hengrui Pharmaceuticals Co., Ltd. granted Novo Nordisk ex-Greater China rights to develop and commercialize HRS-1596, an oral GLP-1/GIP dual agonist. The deal is valued at up to \$2.6 billion, including \$300 million upfront. Designed as a once-weekly oral treatment for obesity and diabetes, the candidate significantly bolsters Novo Nordisk's metabolic portfolio. **(Caixin)**

Shanghai Stock Exchange Launches SSE Innovative Drugs STAR Leading Index

The Shanghai Stock Exchange and China Securities Index Co., Ltd. launched the SSE Innovative Drugs STAR Leading Index. Tracking 40 innovative drug firms across the STAR Market and Main Board, the index selects companies with strong R&D and growth potential. It serves as a new benchmark for biotech equities while accelerating market value discovery. **(Sohu)**